carbidopa has been researched along with tolcapone in 39 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 20 (51.28) | 18.2507 |
| 2000's | 5 (12.82) | 29.6817 |
| 2010's | 13 (33.33) | 24.3611 |
| 2020's | 1 (2.56) | 2.80 |
| Authors | Studies |
|---|---|
| Fisk, L; Greene, N; Naven, RT; Note, RR; Patel, ML; Pelletier, DJ | 1 |
| Ekins, S; Williams, AJ; Xu, JJ | 1 |
| Alelyunas, YW; Bui, K; Empfield, JR; McCarthy, D; Pelosi-Kilby, L; Shen, C; Spreen, RC | 1 |
| Chen, M; Fang, H; Liu, Z; Shi, Q; Tong, W; Vijay, V | 1 |
| Cantin, LD; Chen, H; Kenna, JG; Noeske, T; Stahl, S; Walker, CL; Warner, DJ | 1 |
| Afshari, CA; Chen, Y; Dunn, RT; Hamadeh, HK; Kalanzi, J; Kalyanaraman, N; Morgan, RE; van Staden, CJ | 1 |
| Chen, M; Hu, C; Suzuki, A; Thakkar, S; Tong, W; Yu, K | 1 |
| Jones, LH; Nadanaciva, S; Rana, P; Will, Y | 1 |
| Männistö, PT; Tuomainen, P; Tuominen, RK | 1 |
| Abe, T; Saheki, M; Takahashi, S; Tohgi, H; Tsukamoto, Y; Yamazaki, K | 1 |
| Burns, RS; Davis, TL; Roznoski, M | 2 |
| Lang, A; Männistö, PT; Rauhala, P; Vasar, E | 1 |
| Männistö, PT; Törnwall, M | 1 |
| Amantea, MA; Bravi, D; Chase, TN; Cora-Locatelli, G; Mouradian, MM; Roberts, JW | 1 |
| Kaakkola, S; Wurtman, RJ | 1 |
| Da Prada, M; Dingemanse, J; Zürcher, G | 1 |
| Ishii, S; Ishiwata, K; Nozaki, T; Senda, M; Shinoda, M | 1 |
| Burns, RS; Jorga, K; Leese, P; Schmitt, M; Sêdek, G | 1 |
| Budygin, EA; Gaĭnetdinov, RR; Mannisto, PT; Raevskiĭ, KS | 1 |
| Aitken, J; Fotteler, B; Jorga, K; Nielsen, T; Sedek, G | 1 |
| Goetz, CG | 1 |
| Adler, CH; Deptula, D; Dorflinger, E; Hauser, RA; Lew, MF; Marek, KL; O'Brien, C; Pedder, S; Singer, C; Yoo, K | 1 |
| Dajani, EZ; Dajani, NE; Dayton, MT; Larsen, KR; Moore, JG | 1 |
| Jorga, KM; Nicholl, DJ | 1 |
| Stacy, M | 1 |
| Ahlskog, JE | 1 |
| Banken, L; Fotteler, B; Jorga, K; Snell, P; Steimer, JL | 1 |
| Gainetdinov, R; Huotari, M; Männistö, PT | 1 |
| Chernik, D; Dorflinger, E; Waters, C; Welsh, MD | 1 |
| Bonoma, RA; Iwuagwu, CU; Riley, D | 1 |
| Iwata, S; Kaseda, S; Nomoto, M | 1 |
| Gerlach, M; Kuhn, W; Lehnfeld, R; Riederer, P; Sontag, KH; Waldmeier, P; Xiao, AY | 1 |
| Adamiak, U; Bialecka, M; Gawronska-Szklarz, B; Kaldonska, M; Klodowska-Duda, G; Safranow, K; Wyska, E | 1 |
| Eggert, K; Eichhorn, T; Oertel, WH; Ries, V; Selzer, R | 1 |
| Herrmann, L; Muhlack, S; Müller, T; Salmen, S | 1 |
| Bell, B; Buyan-Dent, L; Christian, BT; Gallagher, CL; Harding, SJ; Holden, JE; Johnson, SC; Nickles, RJ; Oh, J; Okonkwo, O; Palotti, M; Sojkova, J; Stone, CK | 1 |
| Cardoso, MA; de Carvalho, KA; de Francisco, TM; de Oliveira Vilhena, R; Gasparetto, JC; Guimarães de Francisco, TM; Martins, CA; Pontarolo, R; Ribeiro, RP | 1 |
| Boleková, V; Gmitterová, K; Košutzká, Z; Matejička, P; Minár, M; Valkovič, P | 1 |
3 review(s) available for carbidopa and tolcapone
| Article | Year |
|---|---|
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.
Topics: Chemical and Drug Induced Liver Injury; Databases, Factual; Drug Labeling; Humans; Pharmaceutical Preparations; Risk | 2016 |
Medical treatment of later-stage motor problems of Parkinson disease.
Topics: Amantadine; Antiparkinson Agents; Benzophenones; Carbidopa; Catechol O-Methyltransferase Inhibitors; Catechols; Cholinergic Antagonists; Dopamine Agonists; Dose-Response Relationship, Drug; Drug Combinations; Dyskinesia, Drug-Induced; Enzyme Inhibitors; Humans; Levodopa; Nitriles; Nitrophenols; Parkinson Disease, Secondary; Propranolol; Randomized Controlled Trials as Topic; Selegiline; Tolcapone | 1999 |
[Pharmacological treatments of Parkinson's disease].
Topics: Amantadine; Animals; Antiparkinson Agents; Aromatic Amino Acid Decarboxylase Inhibitors; Benzophenones; Carbidopa; Catechol O-Methyltransferase Inhibitors; Dopamine Agonists; Enzyme Inhibitors; Genetic Therapy; Humans; Levodopa; Monoamine Oxidase Inhibitors; Nitrophenols; Parkinson Disease; Receptors, N-Methyl-D-Aspartate; Tolcapone | 2001 |
11 trial(s) available for carbidopa and tolcapone
| Article | Year |
|---|---|
Effects of tolcapone in Parkinson's patients taking L-dihydroxyphenylalanine/carbidopa and selegiline.
Topics: Aged; Antiparkinson Agents; Benzophenones; Carbidopa; Catechol O-Methyltransferase Inhibitors; Dose-Response Relationship, Drug; Drug Administration Schedule; Drug Therapy, Combination; Female; Humans; Levodopa; Male; Middle Aged; Neurologic Examination; Nitrophenols; Parkinson Disease; Selegiline; Tolcapone | 1995 |
Catechol-O-methyltransferase inhibitor tolcapone prolongs levodopa/carbidopa action in parkinsonian patients.
Topics: Adolescent; Adult; Aged; Benzophenones; Carbidopa; Catechol O-Methyltransferase Inhibitors; Drug Synergism; Humans; Levodopa; Middle Aged; Nitrophenols; Parkinson Disease, Secondary; Placebos; Tolcapone | 1993 |
Acute effects of COMT inhibition on L-DOPA pharmacokinetics in patients treated with carbidopa and selegiline.
Topics: Aged; Antiparkinson Agents; Benzophenones; Carbidopa; Dose-Response Relationship, Drug; Humans; Levodopa; Movement Disorders; Nitrophenols; Parkinson Disease; Selegiline; Tolcapone | 1995 |
Effect of tolcapone on plasma levodopa concentrations after coadministration with levodopa/carbidopa to healthy volunteers.
Topics: Adolescent; Adult; Antiparkinson Agents; Area Under Curve; Benzophenones; Biotransformation; Carbidopa; Cross-Over Studies; Drug Combinations; Half-Life; Humans; Levodopa; Male; Middle Aged; Nitrophenols; Single-Blind Method; Tolcapone | 1997 |
The effect of tolcapone on levodopa pharmacokinetics is independent of levodopa/carbidopa formulation.
Topics: Administration, Oral; Adult; Antiparkinson Agents; Benzophenones; Biological Availability; Carbidopa; Delayed-Action Preparations; Dose-Response Relationship, Drug; Drug Interactions; Humans; Levodopa; Male; Middle Aged; Nitrophenols; Parkinson Disease; Tolcapone | 1998 |
Randomized, placebo-controlled study of tolcapone in patients with fluctuating Parkinson disease treated with levodopa-carbidopa. Tolcapone Fluctuator Study Group III.
Topics: Aged; Antiparkinson Agents; Benzophenones; Carbidopa; Catechol O-Methyltransferase Inhibitors; Double-Blind Method; Drug Administration Schedule; Female; Humans; Levodopa; Male; Middle Aged; Nitrophenols; Parkinson Disease; Tolcapone; Treatment Outcome | 1998 |
COMT inhibition with tolcapone does not affect carbidopa pharmacokinetics in parkinsonian patients in levodopa/carbidopa (Sinemet).
Topics: Aged; Antiparkinson Agents; Benzophenones; Carbidopa; Catechol O-Methyltransferase; Catechol O-Methyltransferase Inhibitors; Drug Combinations; Drug Interactions; Enzyme Inhibitors; Female; Humans; Levodopa; Male; Middle Aged; Nitrophenols; Parkinson Disease; Tolcapone | 1999 |
Population pharmacokinetics of tolcapone in parkinsonian patients in dose finding studies.
Topics: Adult; Aged; Aged, 80 and over; Analysis of Variance; Antiparkinson Agents; Area Under Curve; Benserazide; Benzophenones; Carbidopa; Catechol O-Methyltransferase Inhibitors; Enzyme Inhibitors; Female; Humans; Levodopa; Male; Middle Aged; Models, Statistical; Nitrophenols; Parkinson Disease; Population; Risk Factors; Single-Blind Method; Tolcapone | 2000 |
Illness impact and adjustment to Parkinson's disease: before and after treatment with tolcapone.
Topics: Adaptation, Psychological; Adult; Aged; Antiparkinson Agents; Benzophenones; Carbidopa; Dose-Response Relationship, Drug; Double-Blind Method; Drug Therapy, Combination; Female; Humans; Levodopa; Male; Middle Aged; Nitrophenols; Parkinson Disease; Quality of Life; Sick Role; Sickness Impact Profile; Tolcapone; Treatment Outcome | 2000 |
Pharmacokinetic-pharmacodynamic modeling of levodopa in patients with advanced Parkinson disease.
Topics: Age of Onset; Aged; Antiparkinson Agents; Aromatic Amino Acid Decarboxylase Inhibitors; Benserazide; Benzophenones; Carbidopa; Catechol O-Methyltransferase Inhibitors; Drug Combinations; Drug Therapy, Combination; Dyskinesias; Enzyme Inhibitors; Female; Half-Life; Humans; Levodopa; Male; Metabolic Clearance Rate; Middle Aged; Models, Biological; Nitrophenols; Parkinson Disease; Severity of Illness Index; Tolcapone; Tyrosine | 2010 |
Replacing a dopamine agonist by the COMT-inhibitor tolcapone as an adjunct to L-dopa in the treatment of Parkinson's disease: a randomized, multicenter, open-label, parallel-group study.
Topics: Aged; Ambulatory Care Facilities; Aromatic Amino Acid Decarboxylase Inhibitors; Benserazide; Benzophenones; Carbidopa; Catechol O-Methyltransferase Inhibitors; Dopamine Agonists; Drug Combinations; Drug Therapy, Combination; Dyskinesias; Enzyme Inhibitors; Feasibility Studies; Female; Humans; Levodopa; Male; Middle Aged; Nitrophenols; Parkinson Disease; Severity of Illness Index; Time Factors; Tolcapone; Treatment Outcome | 2010 |
25 other study(ies) available for carbidopa and tolcapone
| Article | Year |
|---|---|
Developing structure-activity relationships for the prediction of hepatotoxicity.
Topics: Chemical and Drug Induced Liver Injury; Databases, Factual; Humans; Structure-Activity Relationship; Tetracyclines; Thiophenes | 2010 |
A predictive ligand-based Bayesian model for human drug-induced liver injury.
Topics: Bayes Theorem; Chemical and Drug Induced Liver Injury; Humans; Ligands | 2010 |
Experimental solubility profiling of marketed CNS drugs, exploring solubility limit of CNS discovery candidate.
Topics: Central Nervous System Agents; Drug Evaluation, Preclinical; Hydrogen-Ion Concentration; Pharmaceutical Preparations; Solubility | 2010 |
FDA-approved drug labeling for the study of drug-induced liver injury.
Topics: Animals; Benchmarking; Biomarkers, Pharmacological; Chemical and Drug Induced Liver Injury; Drug Design; Drug Labeling; Drug-Related Side Effects and Adverse Reactions; Humans; Pharmaceutical Preparations; Reproducibility of Results; United States; United States Food and Drug Administration | 2011 |
Mitigating the inhibition of human bile salt export pump by drugs: opportunities provided by physicochemical property modulation, in silico modeling, and structural modification.
Topics: Animals; ATP Binding Cassette Transporter, Subfamily B, Member 11; ATP-Binding Cassette Transporters; Bile Acids and Salts; Cell Line; Chemical and Drug Induced Liver Injury; Humans; Quantitative Structure-Activity Relationship | 2012 |
A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development.
Topics: Animals; ATP Binding Cassette Transporter, Subfamily B; ATP Binding Cassette Transporter, Subfamily B, Member 11; ATP-Binding Cassette Transporters; Biological Transport; Chemical and Drug Induced Liver Injury; Cluster Analysis; Drug-Related Side Effects and Adverse Reactions; Humans; Liver; Male; Multidrug Resistance-Associated Proteins; Pharmacokinetics; Rats; Rats, Sprague-Dawley; Recombinant Proteins; Risk Assessment; Risk Factors; Toxicity Tests | 2013 |
Development of a cell viability assay to assess drug metabolite structure-toxicity relationships.
Topics: Adenosine Triphosphate; Benzbromarone; Cell Line; Cell Survival; Chromans; Cytochrome P-450 CYP2C9; Cytochrome P-450 CYP2D6; Cytochrome P-450 CYP3A; Cytochrome P-450 Enzyme System; Humans; Pharmaceutical Preparations; Thiazolidinediones; Troglitazone | 2016 |
Different in vivo properties of three new inhibitors of catechol O-methyltransferase in the rat.
Topics: Amidines; Animals; Benzophenones; Biogenic Monoamines; Brain; Carbidopa; Catechol O-Methyltransferase Inhibitors; Catechols; Corpus Striatum; Homovanillic Acid; Hypothalamus; Levodopa; Male; Methyldopa; Nitriles; Nitrophenols; Pyridones; Rats; Rats, Inbred Strains; Tolcapone | 1992 |
Effects of the catechol-O-methyltransferase inhibitor tolcapone in Parkinson's disease: correlations between concentrations of dopaminergic substances in the plasma and cerebrospinal fluid and clinical improvement.
Topics: 3,4-Dihydroxyphenylacetic Acid; Aged; Antiparkinson Agents; Benzophenones; Carbidopa; Catechol O-Methyltransferase Inhibitors; Dopamine; Homovanillic Acid; Humans; Levodopa; Middle Aged; Nitrophenols; Parkinson Disease; Tolcapone; Tyrosine | 1995 |
Beneficial effects of co-administration of catechol-O-methyltransferase inhibitors and L-dihydroxyphenylalanine in rat models of depression.
Topics: Analysis of Variance; Animals; Avoidance Learning; Behavior, Animal; Benzophenones; Carbidopa; Catechol O-Methyltransferase Inhibitors; Catechols; Depression; Desipramine; Dihydroxyphenylalanine; Disease Models, Animal; Drug Synergism; Drug Therapy, Combination; Levodopa; Male; Motor Activity; Nitriles; Nitrophenols; Rats; Rats, Wistar; Swimming; Tolcapone | 1995 |
Effects of three types of catechol O-methylation inhibitors on L-3,4-dihydroxyphenylalanine-induced circling behaviour in rats.
Topics: Amidines; Amphetamine; Animals; Behavior, Animal; Benzophenones; Carbidopa; Catechol O-Methyltransferase Inhibitors; Catechols; Clorgyline; Drug Interactions; Drug Synergism; Levodopa; Male; Methylation; Nitriles; Nitrophenols; Pyridones; Rats; Rats, Wistar; Tolcapone | 1993 |
Effects of catechol-O-methyltransferase inhibitors and L-3,4-dihydroxyphenylalanine with or without carbidopa on extracellular dopamine in rat striatum.
Topics: Animals; Benzophenones; Carbidopa; Catechol O-Methyltransferase Inhibitors; Catechols; Corpus Striatum; Dihydroxyphenylalanine; Dopamine; Extracellular Space; Male; Nitriles; Nitrophenols; Rats; Rats, Sprague-Dawley; Tolcapone; Tyrosine | 1993 |
Potent COMT inhibition by Ro 40-7592 in the periphery and in the brain. Preclinical and clinical findings.
Topics: Animals; Benserazide; Benzophenones; Brain; Carbidopa; Catechol O-Methyltransferase; Catechol O-Methyltransferase Inhibitors; Dose-Response Relationship, Drug; Erythrocytes; Homovanillic Acid; Humans; Levodopa; Male; Nitrophenols; Peripheral Nerves; Rats; S-Adenosylhomocysteine; S-Adenosylmethionine; Tolcapone | 1993 |
Synthesis and evaluation of an 18F-labeled dopa prodrug as a PET tracer for studying brain dopamine metabolism.
Topics: Animals; Benzophenones; Biotransformation; Brain; Carbidopa; Catechol O-Methyltransferase Inhibitors; Cerebral Cortex; Corpus Striatum; Dihydroxyphenylalanine; Dopamine; Enzyme Inhibitors; Fluorine Radioisotopes; Injections, Intravenous; Mice; Nitrophenols; Prodrugs; Time Factors; Tissue Distribution; Tolcapone; Tomography, Emission-Computed | 1996 |
[Effect of subchronic administration of tolcapone on release of striatum dopamine and its metabolites induced by L-DOPA and carbidopa].
Topics: 3,4-Dihydroxyphenylacetic Acid; Animals; Antiparkinson Agents; Benzophenones; Carbidopa; Catechol O-Methyltransferase Inhibitors; Corpus Striatum; Dopamine; Dopamine Agents; Drug Synergism; Enzyme Inhibitors; Homovanillic Acid; Levodopa; Male; Nitrophenols; Rats; Rats, Wistar; Tolcapone | 1998 |
Highlights of the North American and European experiences.
Topics: Antiparkinson Agents; Benserazide; Benzophenones; Carbidopa; Catechol O-Methyltransferase Inhibitors; Dopamine Agents; Double-Blind Method; Drug Combinations; Drug Therapy, Combination; Enzyme Inhibitors; Europe; Humans; Levodopa; Nitrophenols; North America; Parkinson Disease; Randomized Controlled Trials as Topic; Tolcapone | 1998 |
Effects of tolcapone, a catechol-O-methyltransferase inhibitor, and Sinemet on intestinal electrolyte and fluid transport in conscious dogs.
Topics: Animals; Benzophenones; Biological Transport; Carbidopa; Catechol O-Methyltransferase Inhibitors; Dogs; Dose-Response Relationship, Drug; Drug Combinations; Electrolytes; Enzyme Inhibitors; Female; Intestinal Mucosa; Intestinal Secretions; Intestines; Levodopa; Nitrophenols; Tolcapone | 1998 |
Parkinson's disease: therapeutic choices and timing decisions in patient management. Interview by Wayne Kuznar.
Topics: Age Factors; Aged; Antiparkinson Agents; Benzophenones; Carbidopa; Disease Progression; Drug Administration Schedule; Electric Stimulation Therapy; Humans; Levodopa; Middle Aged; Nitrophenols; Parkinson Disease; Patient Selection; Selegiline; Time Factors; Tolcapone | 1999 |
Microdialysis studies on the action of tolcapone on pharmacologically-elevated extracellular dopamine levels in conscious rats.
Topics: 3,4-Dihydroxyphenylacetic Acid; 8-Hydroxy-2-(di-n-propylamino)tetralin; Animals; Benzophenones; Carbidopa; Catechol O-Methyltransferase; Dopamine; Dopamine Antagonists; Dopamine Uptake Inhibitors; Drug Interactions; Enzyme Inhibitors; Extracellular Space; Haloperidol; Homovanillic Acid; Levodopa; Male; Microdialysis; Nitrophenols; Piperazines; Rats; Rats, Wistar; Time Factors; Tolcapone; Visual Cortex | 1999 |
Neuroleptic malignant-like syndrome in an elderly patient caused by abrupt withdrawal of tolcapone, a-catechol-o-methyl transferase inhibitor.
Topics: Aged; Aged, 80 and over; Akathisia, Drug-Induced; Antiparkinson Agents; Benzophenones; Carbidopa; Catechol O-Methyltransferase Inhibitors; Confusion; Female; Humans; Levodopa; Neuroleptic Malignant Syndrome; Nitrophenols; Substance Withdrawal Syndrome; Tolcapone | 2000 |
The central catechol-O-methyltransferase inhibitor tolcapone increases striatal hydroxyl radical production in L-DOPA/carbidopa treated rats.
Topics: 3,4-Dihydroxyphenylacetic Acid; Animals; Antiparkinson Agents; Benzophenones; Carbidopa; Catechol O-Methyltransferase Inhibitors; Catechols; Corpus Striatum; Dopamine; Dose-Response Relationship, Drug; Hydroxyl Radical; Levodopa; Male; Microdialysis; Nitriles; Nitrophenols; Oxidative Stress; Parkinsonian Disorders; Rats; Rats, Wistar; Tolcapone | 2001 |
Fewer fluctuations, higher maximum concentration and better motor response of levodopa with catechol-O-methyltransferase inhibition.
Topics: Aged; Antiparkinson Agents; Area Under Curve; Benzophenones; Carbidopa; Catechol O-Methyltransferase Inhibitors; Catechols; Dose-Response Relationship, Drug; Female; Humans; Levodopa; Male; Middle Aged; Motor Activity; Nitriles; Nitrophenols; Parkinson Disease; Psychomotor Performance; Statistics, Nonparametric; Tolcapone; Treatment Outcome | 2014 |
Anterior cingulate dopamine turnover and behavior change in Parkinson's disease.
Topics: Adult; Aged; Aged, 80 and over; Antiparkinson Agents; Benzophenones; Carbidopa; Catechol O-Methyltransferase; Catechol O-Methyltransferase Inhibitors; Dopamine; Female; Gyrus Cinguli; Humans; Male; Middle Aged; Neuropsychological Tests; Nitrophenols; Parkinson Disease; Positron-Emission Tomography; Radiopharmaceuticals; Tolcapone | 2015 |
Simultaneous determination of levodopa, carbidopa, entacapone, tolcapone, 3-O-methyldopa and dopamine in human plasma by an HPLC-MS/MS method.
Topics: Benzophenones; Blood Chemical Analysis; Carbidopa; Catechols; Chromatography, High Pressure Liquid; Dihydroxyphenylalanine; Dopamine; Humans; Levodopa; Nitriles; Nitrophenols; Quality Control; Reproducibility of Results; Tandem Mass Spectrometry; Tolcapone; Tyrosine | 2015 |
Tolcapone improves outcomes in patients with Parkinson disease treated by levodopa/carbidopa intestinal gel: A pilot study.
Topics: Antiparkinson Agents; Carbidopa; Catechol O-Methyltransferase; Drug Combinations; Homocysteine; Humans; Levodopa; Parkinson Disease; Pilot Projects; Quality of Life; Tolcapone | 2022 |